INT229279

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2007
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 9.40
Pain Relevance 0.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Cby1) Golgi apparatus (Cby1) nucleus (Cby1)
Anatomy Link Frequency
coronary artery 1
Cby1 (Mus musculus)
Pain Link Frequency Relevance Heat
Bile 365 89.00 High High
Inflammation 32 86.84 High High
agonist 65 53.92 Quite High
Kinase C 1 6.56 Low Low
alcohol 33 5.00 Very Low Very Low Very Low
nud 18 5.00 Very Low Very Low Very Low
Angina 11 5.00 Very Low Very Low Very Low
Bioavailability 10 5.00 Very Low Very Low Very Low
antagonist 10 5.00 Very Low Very Low Very Low
Migraine 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 1089 100.00 Very High Very High Very High
Diabetes Mellitus 310 99.48 Very High Very High Very High
Coronary Artery Disease 249 98.78 Very High Very High Very High
Chronic Renal Failure 64 98.12 Very High Very High Very High
Atherosclerosis 282 97.90 Very High Very High Very High
Cardiovascular Disease 79 91.92 High High
Pressure Volume 2 Under Development 3 91.84 High High
Hyperlipidemia 73 91.72 High High
Vasculitis 6 86.84 High High
Hyperlipoproteinemia Type Ii 56 83.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Finally, in a 16-week study of 287 men and women with T2DM treated with insulin monotherapy or insulin in combination with OAD, colesevelam HCl six 625-mg tablets per day decreased LDL-C by 12.8%, non-significantly decreased HDL-C by 0.9%, and significantly increased TG by 21.5%.
Negative_regulation (decreased) of C by associated with diabetes mellitus and disorder of lipid metabolism
1) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 0.66 Pain Relevance 0
Compared with the placebo group, both treatment regimens decreased LDL-C by 38% and CRP by 38%–40% after 28 days (P < 0.01 for both compared with placebo).
Negative_regulation (decreased) of C by
2) Confidence 0.42 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988620 Disease Relevance 0.32 Pain Relevance 0.04
While simvastatin plus ezetimibe decreased LDL-C by 57%, HDL-C only increased by 10% compared to baseline.
Negative_regulation (decreased) of C by associated with disorder of lipid metabolism
3) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2464766 Disease Relevance 0.61 Pain Relevance 0
Rosuvastatin (10–40 mg) monotherapy decreased LDL-C by 53% and raised HDL-C by 7% (Jones 2006).
Negative_regulation (decreased) of C by associated with disorder of lipid metabolism
4) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2464766 Disease Relevance 0.63 Pain Relevance 0.03
Rosuvastatin (10–40 mg) monotherapy decreased LDL-C by 53% and raised HDL-C by 7% (Jones 2006).
Negative_regulation (decreased) of C by associated with disorder of lipid metabolism
5) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2464766 Disease Relevance 0.63 Pain Relevance 0.03
Thomas Arteriosclerosis Regression Study (STARS) of 90 men with CHD treated with cholestyramine 16 g/day for 3 years revealed a decrease in LDL-C by 35.7%, and increase in HDL-C by 4%, associated with decreased progression and increased regression of atherosclerotic coronary artery lesions compared to “usual care” therapy (Watts et al 1992).


Negative_regulation (decrease) of C by in coronary artery associated with coronary artery disease, atherosclerosis and disorder of lipid metabolism
6) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 1.10 Pain Relevance 0.04
Early statin combination trials demonstrated that compared with statin alone, six 625-mg colesevelam HCl tablets per day in combination with statins, further decreased LDL-C by 10%–16%, increased HDL-C by 3%–7%, and increased TG levels by 5%–23%.
Negative_regulation (decreased) of C by associated with disorder of lipid metabolism
7) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 0.19 Pain Relevance 0.06
In a 26-week study of 316 men and women with T2DM and treated with metformin monotherapy, or metformin combined with other OAD, colesevelam HCl six 625-mg tablets per day decreased LDL-C by 15.9% and increased HDL-C 0.9%, with a non-statistically significant increase in TG levels of 4.7%.
Negative_regulation (decreased) of C by associated with diabetes mellitus and disorder of lipid metabolism
8) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 0.66 Pain Relevance 0
Early monotherapy trials demonstrated that compared to placebo, six 625 mg tablets colesevelam HCl per day decreased LDL-C by 15%–21%, increased HDL-C by 3%–9%, and increased TG levels by 2%–16% compared with placebo (Bays and Dujovne 2003).
Negative_regulation (decreased) of C by associated with disorder of lipid metabolism
9) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 0.17 Pain Relevance 0.07
In another 26-week study of 461 men and women with T2DM treated with sulfonylurea monotherapy, or combined with other OAD, colesevelam HCl six 625-mg tablets per day decreased LDL-C by 16.7%, non-statistically increased HDL-C by 0.1%, and increased TG levels by 17.7%.
Negative_regulation (decreased) of C by associated with diabetes mellitus and disorder of lipid metabolism
10) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 0.71 Pain Relevance 0
When combined with fenofibrate, colesevelam HCl decreased LDL-C by 12.7% compared with fenofibrate monotherapy, with no statistically significant effect on TG levels (McKenney et al 2005), which may have clinical relevance for hypertriglyceridemic patients with persistent hypercholesterolemia after fibrate therapy.


Negative_regulation (decreased) of C by associated with hyperlipidemia
11) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 0.42 Pain Relevance 0
Finally, in a 16-week study of 287 men and women with T2DM treated with insulin monotherapy or insulin in combination with OAD, colesevelam HCl six 625-mg tablets per day decreased LDL-C by 12.8%, non-significantly decreased HDL-C by 0.9%, and significantly increased TG by 21.5%.
Negative_regulation (decreased) of C by associated with diabetes mellitus and disorder of lipid metabolism
12) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 0.66 Pain Relevance 0
In a 6-week (for each period) crossover study of 20 men and one woman with T2DM, cholestyramine 16 g/day decreased LDL-C by 28%, had no significant change in HDL-C, and increased triglyceride (TG) levels 13.5%.
Negative_regulation (decreased) of C by associated with diabetes mellitus and disorder of lipid metabolism
13) Confidence 0.42 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 1.06 Pain Relevance 0.04
ACE inhibitor or ARB monotherapy, in doses commonly used in clinical practice does not result in complete suppression of the RAAS.
Negative_regulation (inhibitor) of ARB
14) Confidence 0.01 Published 2010 Journal Cardiovasc Drugs Ther Section Abstract Doc Link PMC2887501 Disease Relevance 1.06 Pain Relevance 0
Although the differing delivery methods make comparison of the present results somewhat difficult, it does appear that the application of a low dose of APA was equivalent to an ARB and ACE inhibitor with respect to antihypertensive efficacy.
Negative_regulation (inhibitor) of ARB
15) Confidence 0.00 Published 2011 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC3005972 Disease Relevance 0.52 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox